Ranbaxy gets nod to market Risperidone oral solution

Mumbai, Aug 4 (UNI) Ranbaxy Laboratories has received a tentative approval from the US Food and Drug Administration (USFDA) to manufacture Risperidone oral solution 1 mg/ml, prescribed for the treatment of schizophrenia.

A company release to the Bombay Stock Exchange today said the total annual market sales for risperidone oral solution were USD 66 million.

Company's vice-president (sales&marketing) Jim Meehan said, ''We are pleased to receive a tentative approval for Risperidone oral solution. The product represents a future opportunity for Ranbaxy and will be launched following final approval from USFDA.'' Ranbaxy Pharmaceutical Inc, which is based in Jacksonville, Florida in the US, is a wholly-owned subsidiary of the company. It is engaged in the sale and distribution of generic and branded prescription products in the US.

UNI SN WD GK VKG1832